Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Identifying intratumoral transcriptional heterogeneity in BCR-ABL1 lymphoblastic leukemia
EF 2018-19
Résumé
BCR-ABL1 acute lymphoblastic leukemia (ALL) is the most common form of ALL in adults, contributing to 25-40% of cases. The development of drugs that inhibit BCR-ABL1, such as imatinib, has improved clinical outcomes for BCR-ABL1 ALL patients, yet many patients still relapse for reasons not entirely known. One contributor to relapse in the disease is the persistence of treatment-resistant leukemic subpopulations that are sufficient to restart the disease. Recent research in the Notta lab has demonstrated that BCR-ABL1 ALL patients can be separated into two subgroups, ‘core-B’ and ‘mixed-B’, with different molecular profiles and treatment outcomes. To better understand the subgroups and why they feature differences in relapse rates, I will identify the extent of intratumoral heterogeneity in samples from the ‘core-B’ and ‘mixed-B’ subgroups and characterize the resulting cell subpopulations using single-cell RNA sequencing. I plan to analyze the single-cell data by applying novel machine learning approaches to cluster cells. I will identify the cell populations we find from this clustering by comparing to known transcriptional profiles of leukemic and normal cells. Finally, I will compare the composition of cell populations between samples from the ‘core-B’ and ‘mixed-B’ groups. Identifying the common and unique subpopulations of blast among the two molecularly and clinically different subgroups will help with developing therapies that target all cancerous populations and prevent relapse.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406292
Name
Ge Sabrina M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying intratumoral transcriptional heterogeneity in BCR-ABL1 lymphoblastic leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer; Computational Biology; Genomics; Leukemia; Single-Cell Rna-Sequencing; Transcriptomics; Tumour Heterogeneity
Abstract
BCR-ABL1 acute lymphoblastic leukemia (ALL) is the most common form of ALL in adults, contributing to 25-40% of cases. The development of drugs that inhibit BCR-ABL1, such as imatinib, has improved clinical outcomes for BCR-ABL1 ALL patients, yet many patients still relapse for reasons not entirely known. One contributor to relapse in the disease is the persistence of treatment-resistant leukemic subpopulations that are sufficient to restart the disease. Recent research in the Notta lab has demonstrated that BCR-ABL1 ALL patients can be separated into two subgroups, ‘core-B’ and ‘mixed-B’, with different molecular profiles and treatment outcomes. To better understand the subgroups and why they feature differences in relapse rates, I will identify the extent of intratumoral heterogeneity in samples from the ‘core-B’ and ‘mixed-B’ subgroups and characterize the resulting cell subpopulations using single-cell RNA sequencing. I plan to analyze the single-cell data by applying novel machine learning approaches to cluster cells. I will identify the cell populations we find from this clustering by comparing to known transcriptional profiles of leukemic and normal cells. Finally, I will compare the composition of cell populations between samples from the ‘core-B’ and ‘mixed-B’ groups. Identifying the common and unique subpopulations of blast among the two molecularly and clinically different subgroups will help with developing therapies that target all cancerous populations and prevent relapse.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ge, Sabrina M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~